Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage (DFO In ICH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00598572|
Recruitment Status : Completed
First Posted : January 22, 2008
Last Update Posted : January 16, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Animal studies show that the breakdown of blood results in iron accumulation in the brain after brain hemorrhage (ICH); and that iron plays a role in brain injury in ICH patients. Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to remove excessive iron from the body, and has been shown to provide some benefit in animal studies of ICH. Therefore, we plan to undertake this study to evaluate the safety and tolerability of treatment with DFO in patients with ICH, and to determine the maximal tolerated dose to be used in future studies to determine if treatment with DFO can improve the outcome of patients with ICH.
Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies to test the efficacy of DFO in improving outcome after ICH.
We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with DFO will improve patients' outcome. The results can potentially bring into account new means to improve the outcome of patients with ICH. ICH is a frequent cause of disability and death. A successful study demonstrating the efficacy of iron-modifying therapy would be of considerable public health significance.
|Condition or disease||Intervention/treatment||Phase|
|Intracerebral Hemorrhage||Drug: Deferoxamine Mesylate||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage|
|Study Start Date :||July 2008|
|Actual Primary Completion Date :||January 2010|
|Actual Study Completion Date :||April 2010|
All participants will receive various dose-regimens of the study drug (deferoxamine mesylate). Each dose cohort will consist of at least 3 subjects.
Drug: Deferoxamine Mesylate
Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
- Dose-limiting toxicities [ Time Frame: First 7 days of hospitalization or diacharge, whichever occurs earlier ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Age ≥ 18 years
- The diagnosis of ICH is confirmed by brain CT scan.
- The first dose of the study drug can be administered within 18 hours of ICH symptom onset.
- Signed and dated informed consent is obtained
- Stable clinical and neurological status. Patients whose clinical or neurological status significantly deteriorates compared to presentation prior to administration of the study drug will be excluded.
- Previous chelation therapy or known hypersensitivity to DFO products
- Abnormal renal function (serum creatinine > 2 mg/dl)
- Known severe iron deficiency anemia
- Planned surgical evacuation of ICH prior to administration of the study drug
- Patients with suspected secondary ICH related to tumour, coagulopathy, ruptured aneurysm or arteriovenous malformation, or venous sinus thrombosis
- Evidence of significant shift of midline brain structure (> 10 mm) or herniation on imaging studies.
- Deep coma (Glasgow Coma Score (GCS) = 3-5) upon presentation
- Taking iron supplements or prochlorperazine
- Patients with heart failure taking > 500 mg of vitamin C daily
- Known hearing impairment
- Systolic blood pressure < 100 mmHg or diastolic blood pressure < 60 mmHg, confirmed by 3 consecutive readings
- Significant chronic respiratory insufficiency
- Known pregnancy (or positive pregnancy test), or breast-feeding
- Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, incompliance, or any other cause.
- Any condition which, in the judgement of the investigator, might increase the risk to the patient
- Life expectancy of less than 90 days due to co-morbid conditions
- Concurrent participation in another research protocol for investigation of another experimental therapy
- Pre-existing Do Not Resuscitate (DNR) order, or indication that a new DNR order will be implemented within the first 48 hours of hospitalization. -
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00598572
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||Magdy Selim, MD, PhD||Beth Israel Deaconess Medical Center|
|Responsible Party:||Magdy Selim, Professor of Neurology, Beth Israel Deaconess Medical Center|
|Other Study ID Numbers:||
1R01NS057127-01A1 ( U.S. NIH Grant/Contract )
|First Posted:||January 22, 2008 Key Record Dates|
|Last Update Posted:||January 16, 2018|
|Last Verified:||January 2018|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
Central Nervous System Diseases
Nervous System Diseases
Iron Chelating Agents
Molecular Mechanisms of Pharmacological Action